{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:16:17Z","timestamp":1761394577877,"version":"3.37.3"},"reference-count":57,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,17]],"date-time":"2014-12-17T00:00:00Z","timestamp":1418774400000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["GE Portuguese Journal of Gastroenterology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.jpge.2014.09.001","type":"journal-article","created":{"date-parts":[[2014,12,19]],"date-time":"2014-12-19T09:50:00Z","timestamp":1418982600000},"page":"221-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A practical guide for antiviral therapy of chronic Hepatitis C"],"prefix":"10.1159","volume":"21","author":[{"given":"Jos\u00e9","family":"Velosa","sequence":"first","affiliation":[]},{"given":"F\u00e1tima","family":"Serejo","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Ramalho","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Marinho","sequence":"additional","affiliation":[]},{"given":"Beatriz","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Cil\u00e9nia","family":"Baldaia","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Raimundo","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Ferreira","sequence":"additional","affiliation":[]}],"member":"127","reference":[{"key":"10.1016\/j.jpge.2014.09.001_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Levanchy","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jpge.2014.09.001_bib0010","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age specific antibody to HCV seroprevalence","volume":"57","author":"Hanafiah","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0015","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/hep.26218","article-title":"Chronic hepatitis C virus (HCV) disease burden and cost in the United States","volume":"57","author":"Razavi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2009.09.067","article-title":"Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression","volume":"138","author":"Davis","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0025","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1053\/j.gastro.2012.05.054","article-title":"Predicted effects of treatment for HCV infection vary among European countries","volume":"143","author":"Deuffic-Burban","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0030","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0035","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s10620-011-1621-2","article-title":"Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis","volume":"56","author":"Velosa","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jpge.2014.09.001_bib0045","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0050","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0055","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","article-title":"Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-na\u00efve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial","volume":"383","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jpge.2014.09.001_bib0065","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0070","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","article-title":"EASL clinical practice guidelines: management of hepatitis C virus infection","volume":"60","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpge.2014.09.001_bib0075","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jpge.2014.09.001_bib0080","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0085","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0090","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.25892","article-title":"Higher sustained virologic response in rapid virologic response patients in the large real-world PROPHESYS cohort confirms results from randomized clinical trials","volume":"56","author":"Marcellin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0095","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0100","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1053\/j.gastro.2009.01.039","article-title":"Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa\/ribavirin therapy","volume":"136","author":"Poynard","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1111\/liv.12439","article-title":"A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40KD)\/ribavirin","author":"Ferenci","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.jpge.2014.09.001_bib0110","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jvh.12106","article-title":"Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis","volume":"20","author":"Di Marco","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jpge.2014.09.001_bib0115","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/hep.23859","article-title":"Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1","volume":"52","author":"Petta","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0120","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","article-title":"Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients","volume":"128","author":"Romero-G\u00f3mez","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0125","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1111\/j.1572-0241.2008.02002.x","article-title":"Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study","volume":"103","author":"Giordanino","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpge.2014.09.001_bib0130","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.23340","article-title":"Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis","volume":"51","author":"Bruno","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jpge.2014.09.001_bib0140","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-2893.2012.01624.x","article-title":"Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a\/ribavirin","volume":"19","author":"Zeuzem","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jpge.2014.09.001_bib0145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2010.10.032","article-title":"Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection","volume":"55","author":"Fried","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpge.2014.09.001_bib0150","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jhep.2013.07.040","article-title":"Identification of naive HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin","volume":"60","author":"Andriulli","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpge.2014.09.001_bib0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.26624","article-title":"Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon\/ribavirin obviates a protease inhibitor","volume":"59","author":"Pearlman","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme","volume":"59","author":"H\u00e9zode","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpge.2014.09.001_bib0165","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0170","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0175","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response guided Telaprevir combination treatment for Hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0180","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1053\/j.gastro.2012.05.011","article-title":"Factors that predict response of patients with hepatitis C virus infection to boceprevir","volume":"143","author":"Poordad","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0185","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2012.11.020","article-title":"Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis\/chirrosis","volume":"58","author":"Bruno","year":"2013","journal-title":"J Hepatol"},{"issue":"Suppl.","key":"10.1016\/j.jpge.2014.09.001_bib0190","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/liv.12067","article-title":"How to optimize HCV therapy in genotype 1 patients with cirrhosis","volume":"33","author":"Bourli\u00e8re","year":"2013","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jpge.2014.09.001_bib0200","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/gutjnl-2013-305771","article-title":"New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C","volume":"63","author":"Mari\u00f1o","year":"2014","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jpge.2014.09.001_bib0205","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"The efficacy and safety of sofosbuvir, a novel oral nucleotide ns5b polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","author":"Koff","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jpge.2014.09.001_bib0210","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s40265-013-0153-9","article-title":"First global approval","volume":"73","author":"Asha","year":"2013","journal-title":"Drug"},{"issue":"12","key":"10.1016\/j.jpge.2014.09.001_bib0215","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1358\/dot.2013.49.12.2067249","article-title":"Simeprevir: a macrocyclic HCV protease inhibitor","volume":"49","author":"Talwani","year":"2013","journal-title":"Drugs Today"},{"key":"10.1016\/j.jpge.2014.09.001_bib0220","first-page":"3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-na\u00efve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomized, double-blind, placebo-controlled trial","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jpge.2014.09.001_bib0225","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-na\u00efve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomized, double-blind, placebo-controlled phase 3 trial","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jpge.2014.09.001_bib0230","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increase rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial","volume":"46","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0235","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapses after previous therapy: a phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jpge.2014.09.001_bib0240","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0245","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0250","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0255","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"unstructured":"Recommendations for testing, managing, and treating hepatitis. ASSLD Guidelines. Available: http:\/\/www.hcvguidelines.org","key":"10.1016\/j.jpge.2014.09.001_bib0260"},{"key":"10.1016\/j.jpge.2014.09.001_bib0265","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0270","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0275","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpge.2014.09.001_bib0280","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/S0168-8278(14)60009-X","article-title":"Once-daily simeprevir (TMC435) plus sofosbuvir (GS7977) with or without ribavirin in HCV genotype 1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis","volume":"60","author":"Sulkwoski","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpge.2014.09.001_bib0285","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C v\u00edrus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized study","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jpge.2014.09.001_bib0290","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"}],"container-title":["GE Portuguese Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S234145451400115X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S234145451400115X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T22:22:21Z","timestamp":1498170141000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S234145451400115X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S234145451400115X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpge.2014.09.001","relation":{},"ISSN":["2341-4545"],"issn-type":[{"type":"print","value":"2341-4545"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A practical guide for antiviral therapy of chronic Hepatitis C","name":"articletitle","label":"Article Title"},{"value":"GE Portuguese Journal of Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.jpge.2014.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Sociedade Portuguesa de Gastrenterologia. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}